Abacavir contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Abacavir}} {{CMG}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Abacavir}} | {{Abacavir}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AZ}} | ||
==CONTRAINDICATIONS== | |||
•ZIAGEN is contraindicated in patients with:previously demonstrated hypersensitivity to abacavir or any other component of the products. | |||
•NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status. | |||
•Moderate or severe hepatic impairment [see Dosage and Administration] . | |||
==References== | ==References== | ||
Revision as of 21:23, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
CONTRAINDICATIONS
•ZIAGEN is contraindicated in patients with:previously demonstrated hypersensitivity to abacavir or any other component of the products.
•NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status.
•Moderate or severe hepatic impairment [see Dosage and Administration] .
References
Adapted from the FDA Package Insert.